Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

In the Media

  • January 24, 2023

The Dales Report: InMed Pharmaceuticals Clinical Trial Program Moving Forward In 2023

InMed’s CEO, Eric A. Adams, joins The Dales Report webcast to talk about the 2023 plans for the company’s rare cannabinoid programs in epidermolysis bullosa (EB), glaucoma and neurodegenerative disease.

Eric explains that InMed expects to complete enrollment of the Phase 2 clinical trial in EB in March, conduct GLP and other preclinical studies in glaucoma to prepare for its clinical trials in 2024 and advance its neurodegenerative disease program in preclinical studies following promising studies demonstrating neuroprotective effects and enhanced neuronal function, which may be relevant for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s.

Eric talks about InMed’s library of patentable cannabinoid analogs.

Read the full article and watch the video on The Dales Report website.

Full Article
Source: The Dales Report

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Latest Articles

Why explore cannabinoids as potential therapeutic targets for neurodegenerative diseases?

In this video, Eric A. Adams explains how the body’s endocannabinoid system has natural cannabinoid receptors throughout the body that interact with cannabinoids and are

Read More
February 1, 2023

The Dales Report: InMed Focused On Clinical Trial Success In 2023

The Dales Report’s Shadd Dales interviews InMed CEO, Eric A. Adams, to talk about the company’s upcoming pharmaceutical development plans for 2023. Eric speaks about

Read More
December 28, 2022

Tribe Webinar: Exploring the Neuroprotective Qualities of Rare Cannabinoids

InMed’s President and CEO, Eric A. Adams, and Senior VP, Preclinical Research and Development, Dr. Eric Hsu, talks about “Exploring the Neuroprotective Qualities of Rare

Read More
November 21, 2022
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent